Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study.
Oral isotretinoin is the most effective choice in the treatment of severe acne. Application of isotretionin to acne has been expanded to treat those patients with less severe but scarring acne who are responding unsatisfactorily to conventional therapies. However, its use is associated with many side effects, some of which can result in very disastrous consequences. Data related with intermittent isotretinoin therapy is still limited. Our aim was to asses the efficacy and tolerability of two different intermittent isotretinoin courses and compare them with conventional isotretinoin treatment. In this multicenter and controlled study, 66 patients with moderate to severe cases were randomized to receive either isotretionin for the first 10 days of each month for 6 months (group 1), or each day in the first month, afterwards the first 10 days of each month for 5 months (group 2) or daily for 6 months (group 3). The drug dosage was 0.5 mg/kg/day in all groups. Patients were followed-up for 12 months. Efficacy values were evaluable for 22 patients in group 1, 19 patients in group 2, and 19 patients in group 3. Acne scores in each group were significantly lower at the end of treatment and follow-up periods (P < 0.001). When patients were evaluated separately as moderate (n = 31) and severe (n = 29), no statistically significant differences were obtained among the treatment protocols in patients with moderate acne. However, there was a significant difference between groups 1 and 3 to the response of the treatments in severe acne patients at the end of follow-up period (P = 0.013). The frequency and severity of isotretionin-related side effects were found to be lower in groups 1 and 2 compared with group 3. Intermittent isotretinoin may represent an effective alternative treatment, especially in moderate acne with a low incidence and severity of side effects. The intermittent isotretinoin can be recommended in those patients not tolerating the classical dosage.
Akman
Ayse
A
Department of Dermatology and Venerology, Akdeniz University School of Medicine, Antalya, Turkey. aakman@akdeniz.edu.tr
Durusoy
Cicek
C
Senturk
Meltem
M
Koc
Cilem Kaya
CK
Soyturk
Durali
D
Alpsoy
Erkan
E
D000152:Acne Vulgaris / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D016896:Treatment Outcome
D003879:Dermatologic Agents; D015474:Isotretinoin
Br J Dermatol. 2000 Jul;143(1):205-6
10886171
J Eur Acad Dermatol Venereol. 2006 Aug;20(7):773-6
16898895
J Am Acad Dermatol. 2006 Apr;54(4):644-6
16546586
Br J Dermatol. 1998 Jul;139(1):99-101
9764156
Br J Dermatol. 1997 Jul;137(1):106-8
9274635
J Eur Acad Dermatol Venereol. 2006 Nov;20(10):1256-60
17062042
J Am Acad Dermatol. 2003 Sep;49(3 Suppl):S218-26
12963898
J Dermatol. 2003 Jul;30(7):572
12928552
Eur J Dermatol. 2001 Nov-Dec;11(6):538-44
11701404
J Am Acad Dermatol. 2001 Aug;45(2):196-207
11464180
Int J Clin Pharmacol Res. 2003;23(2-3):41-6
15018017